LFCR — LIFECORE BIOMEDICAL, INC. \DE\
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1005286 ·
Last close
$4.42
Market Cap
$165.79M
52W High
$5.96
52W Low
$4.22
ADV30
206,397
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 23,193,000 | 4,462,000 | -4,672,000 | -14,980,000 | 225,499,000 | 20,795,000 | 253,937,000 |
| Sep 2025 | 31,109,000 | 7,791,000 | -3,067,000 | -9,991,000 | 235,204,000 | 18,856,000 | 245,741,000 |
| May 2025 | 36,444,000 | 13,982,000 | 2,899,000 | -1,147,000 | 239,342,000 | 8,265,000 | 238,006,000 |
| Feb 2025 | 35,154,000 | 9,845,000 | -2,293,000 | -14,769,000 | 237,693,000 | 5,417,000 | 235,464,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,169,000
Investing CF
$-4,730,000
Financing CF
$3,943,000
CapEx
$-11,730,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-218,095,000
Inventory
$33,801,000
Receivables
$29,133,000
ST Investments
—
EBIT TTM
$-9,226,000
Pretax Income TTM
$-32,077,000
Interest Exp TTM
$22,851,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$129,464,592
EBITDA
$8,242,287
Free Cash Flow
—
Enterprise Value
$342,103,008
Total Cash
$20,795,000
Total Debt
$150,140,992
Shares Out
37,509,407
Trailing EPS
$-1.27
Book Value
$-0.76
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | 232,177,000 | 246,379,000 | — | — |
| May 2025 | 128,867,000 | -12,006,000 | -38,717,000 | 239,342,000 | 238,006,000 | — | -206,000 |
| May 2024 | 128,261,000 | -7,188,000 | 12,013,000 | 253,960,000 | 242,645,000 | — | 257,000 |
| May 2023 | 103,269,000 | -19,720,000 | -99,563,000 | 253,545,000 | 257,775,000 | — | -17,441,000 |
| May 2022 | 111,270,000 | -3,432,000 | -116,715,000 | — | — | — | -22,593,000 |
TTM Snapshot
Revenues TTM
$124,344,000
NetIncome TTM
$-50,191,000
OpCashFlow TTM
$0
Assets (Latest)
$239,342,000
Forward EPS
$-0.82
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $4.42 · call oi: 731 · put oi: 384
Expected Move to 2026-09-18:
±$1.69
(38.12%) —
implied range
$2.74 –
$6.11
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $166.19M | $8.97 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $166.57M | $4.07 | — |
| PYXS | Pyxis Oncology, Inc. | $167.89M | $2.65 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $163.72M | $5.76 | — |
| INDP | Indaptus Therapeutics, Inc. | $171.88M | $1.29 | — |
News headlines (Yahoo Finance, 1h cache)
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026
2026-07-29 20:05 · Yahoo
Lifecore Biomedical Signs Three New Customer Agreements
2026-07-28 11:05 · Yahoo
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-15 20:05 · Yahoo
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market
2026-07-15 13:11 · Yahoo
Can Lifecore Biomedical, Inc. (LFCR) Unlock Long-Term Value Through Expanding Biopharma Collaborations?
2026-06-30 13:11 · Yahoo
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
2026-06-15 11:05 · Yahoo
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook
2026-06-13 05:06 · Yahoo
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
2026-06-02 11:05 · Yahoo
How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations
2026-05-29 01:03 · Yahoo
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
2026-05-21 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.